Table 2. Potentially actionable mutations found in silico in HCC cell lines and IC50 values associated to them. Table showing the mutational characteristics of six commercial cell lines (in silico comparison with Cancer Cell Line Encyclopedia (CCLE) data).
| Cell line | Chr. | Position | Ref. | Alt. | AA change | Gene | Inhibitor name | Inhibitor | IC50 (μM) |
|---|---|---|---|---|---|---|---|---|---|
| Hep-G2 | 4 | 55976843 | A | T | Y357N | KDR | KDRi (So) | SORAFENIB | 3,5 |
| 10 | 43608351 | G | A | D567N | RET | RETi (Re) | REGORAFENIB | 3,1 | |
| 19 | 18279692 | C | A | Y655* | PIK3R2 | PIK3R2i (Bkm) | BUPARLISIB (BKM-120) | 2,8 | |
| SNU-449 | 1 | 156851421 | A | C | D793A | NTRK1 | NTRKi (Cep) | LESTAURTINIB (CEP-701) | 1,6 |
| 10 | 89717696 | T | C | F241L | PTEN | mTORi (Ev) | EVEROLIMUS | 14,6 | |
| HUH-7 | 9 | 93606577 | A | G | K133E | SYK | SYKi (Fos) | FOSTAMATINIB | 12,9 |
| 12 | 18762561 | A | C | I1394L | PIK3C2G | PIK3C2Gi (Bkm) | BUPARLISIB (BKM-120) | 1,7 | |
| 19 | 7141798 | T | C | T858A | INSR | INSRi (Bms) | BMS-754807 | 8,5 | |
| SNU-182 | 3 | 130409498 | T | A | R1033S | PIK3R4 | PIK3R4i (Bkm) | BUPARLISIB (BKM-120) | 0,8 |
| 13 | 29008268 | T | A | E201D | FLT1 | FLT1i (Re) | REGORAFENIB | 4,7 | |
| 19 | 7184495 | G | A | P269L | INSR | INSRi (Bms) | BMS-754807 | 1,5 | |
| SNU-475 | 13 | 28611336 | G | A | T432M | FLT3 | FLT3i (Cep) | LESTAURTINIB (CEP-701) | 2,5 |
| SNU-423 | 3 | 130452809 | C | A | V345F | PIK3R4 | PIK3R4i (Bkm) | BUPARLISIB (BKM-120) | 1,7 |
| 13 | 28913428 | C | T | E789K | FLT1 | FLT1i (Re) | REGORAFENIB | 9,5 |
The table includes Cell line: Cell line name; Chr.: Chromosome number; Position: Genomic location of the mutation in the chromosome; Ref.: Normal nucleotide; Alt.: Altered nucleotide; AA Change: Amino acid change; Gene: Gene name; Inhibitor name: Used throughout this report; Inhibitor: General name and IC50 (μM): Micromolar IC50 concentration for the indicated inhibitor.